Critical Contrast: Sunshine Biopharma (SBFM) and Its Rivals

Sunshine Biopharma (NASDAQ:SBFM) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Sunshine Biopharma to related companies based on the strength of its risk, valuation, analyst recommendations, profitability, dividends, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for Sunshine Biopharma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	0	0	1.50
Sunshine Biopharma Competitors	7797	13888	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given Sunshine Biopharma’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma has less favorable growth aspects than its competitors.

Volatility & Risk

Sunshine Biopharma has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s competitors have a beta of -3.71, suggesting that their average stock price is 471% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sunshine Biopharma and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	-$5.97 million	-0.01
Sunshine Biopharma Competitors	$3.54 billion	$3.18 billion	554.47

Sunshine Biopharma’s competitors have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of Sunshine Biopharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sunshine Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Sunshine Biopharma Competitors	-2,380.38%	-217.94%	-15.54%

Summary

Sunshine Biopharma competitors beat Sunshine Biopharma on 9 of the 13 factors compared.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.